Synsight was a company created in 2013, by two co-founders PhD Computer aided drug design: Cyril Bauvais (CEO) and Guillaume Bollot (CSO). In july 2024, Synsight was acquired by @iktos, an AI drug discovery company. Its tech is based on AI drug design and cell imaging, including a proprietary cell based assay named MTBench, to profile compounds modulators of protein-protein and protein-RNA interactions, and protein agregation.
Looking for a particular SYNSIGHT employee's phone or email?
The SYNSIGHT annual revenue was $19.9 million in 2026.
SYNSIGHT is based in Evry, Ile-de-France.
The NAICS codes for SYNSIGHT are [541, 541713, 54171, 54, 5417].
The SIC codes for SYNSIGHT are [873, 87].